Scientific article

Maladie d’Alzheimer : ce qui a changé en 2023

Published inRevue médicale suisse, vol. 20, no. 856-7, p. 51-54
Publication date2024-01-17

The increasing prevalence of Alzheimer's disease in the general population presents a number of medical, economic and social challenges for the years to come. After 20 years of research with no new treatment option, a new class of drugs is set to be introduced in Europe. Anti-amyloid drugs, which are already available in the United-States, slow the disease progression by targeting the biological processes causing the disease, unlike the symptomatic treatments that are currently available. However, their precise indications and the monitoring of their adverse events are still to be defined. Several other drugs are in advanced stages of development, such as those targeting the tau protein or neuroinflammation, suggesting that the management of the disease will be quite different in the years to come.

  • Humans
  • Alzheimer Disease / diagnosis
  • Alzheimer Disease / drug therapy
  • Alzheimer Disease / epidemiology
  • Disease Progression
  • Europe
Citation (ISO format)
DONAYRE, Dylan et al. Maladie d’Alzheimer : ce qui a changé en 2023. In: Revue médicale suisse, 2024, vol. 20, n° 856-7, p. 51–54. doi: 10.53738/REVMED.2024.20.856-7.51
Main files (1)
Article (Published version)
accessLevelRestrictedaccessLevelPublic 07/18/2025
ISSN of the journal1660-9379

Technical informations

Creation03/26/2024 2:17:09 PM
First validation05/15/2024 1:01:00 PM
Update time05/15/2024 1:01:00 PM
Status update05/15/2024 1:01:00 PM
Last indexation05/15/2024 1:01:21 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack